Clinical Trial Investigating Pazopanib in Patients With Platinum-resistant Advanced Ovarian Cancer
Phase II, Multicenter, Prospective, Single Arm, Open Labeled Clinical Trial Investigating Pazopanib, a Multi-targeted Tyrosine Kinase Inhibitor (TKI) of VEGFR-1, -2, -3, PDGFR-α and -β and c-Kit in Patients With Platinum-resistant Advanced Ovarian Cancer.
Sponsor: Grupo Español de Investigación en Cáncer de Ovario
A PHASE2 clinical study on Platinum-resistant Advanced Ovarian Cancer, this trial is completed. The trial is conducted by Grupo Español de Investigación en Cáncer de Ovario and has accumulated 6 data snapshots since 2010. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Grupo Español de Investigación en Cáncer de Ovario
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alcorcón, Spain , Barcelona, Spain , Córdoba, Spain , L'Hospitalet de Llobregat, Spain , Madrid, Spain , Manresa, Spain , Murcia, Spain , Palma de Mallorca, Spain , Sabadell, Spain , Santander, Spain and 2 more locations